Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Voriconazole Hikma (previously Voriconazole Hospira)

Voriconazole Hikma 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 11

HOS-130928 · Präparat HOS-096981

Medicinal product Interaction Recommendations concerning geometric mean changes (%) coadministration Antacids Cimetidine (400 mg BID) Voriconazole Cmax ↑ 18% No dose adjustment [non-specific CYP450 inhibitor Voriconazole AUCτ ↑ 23% and increases gastric pH] Omeprazole (40 mg QD)* Omeprazole Cmax ↑ 116% No dose adjustment of [CYP2C19 inhibitor; Omeprazole AUCτ ↑ 280% voriconazole is recommended. CYP2C19 and CYP3A4 Voriconazole Cmax ↑ 15% substrate] Voriconazole AUCτ ↑ 41% When initiating voriconazole in patients already receiving Other proton pump inhibitors omeprazole doses of 40 mg or that are CYP2C19 substrates above, it is recommended that may also be inhibited by the omeprazole dose be halved. voriconazole and may result in increased plasma concentrations of these medicinal products. Ranitidine (150 mg BID) Voriconazole Cmax and AUCτ ↔ No dose adjustment [increases gastric pH] Antiarrhythmics Digoxin (0.25 mg QD) Digoxin Cmax ↔ No dose adjustment [P-gp substrate] Digoxin AUCτ ↔ Quinidine Although not studied, increased Contraindicated (see section [CYP3A4 substrate] plasma concentrations of quinidine 4.3) can lead to QTc prolongation and rare occurrences of torsades de pointes. Antibacterials Flucloxacillin Significantly decreased plasma If concomitant administration of [CYP450 inducer] voriconazole concentrations have voriconazole with flucloxacillin been reported. cannot be avoided, monitor for potential loss of voriconazole effectiveness (e.g., by therapeutic drug monitoring); increasing the dose of voriconazole may be needed. Macrolide antibiotics No dose adjustment

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cimetidine (HOS-085835) quinidine (HOS-085593) digoxin (HOS-086172) lead (HOS-085592) ranitidine (HOS-085660) omeprazole (HOS-085912)